Mike E. Platt
Amministratore Delegato presso BlueCrest Capital Management Ltd. (Jersey)
Relazioni attive
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
Giuseppe Mazza | M | - |
Engitix Ltd.
Engitix Ltd. Miscellaneous Commercial ServicesCommercial Services Engitix Ltd. is a preclinical stage biopharma British company that is developing breakthrough therapies for fibrosis and solid tumors using its patient-centric human extracellular matrix drug discovery platform. The company has drug discovery partnerships with Dompe Farmaceutici and Takeda for advanced fibrotic liver diseases and fibrostenotic inflammatory bowel disease. Engitix was established in 2016 to commercialize research from the Institute for Liver and Digestive Health at University College London. The company is headquartered in WestWorks, London, UK. Giuseppe Mazza and Massimo Pinzani founded the company, and Giuseppe Mazza has been the CEO since 2016. | 8 anni |
David Dally | M | - |
Engitix Ltd.
Engitix Ltd. Miscellaneous Commercial ServicesCommercial Services Engitix Ltd. is a preclinical stage biopharma British company that is developing breakthrough therapies for fibrosis and solid tumors using its patient-centric human extracellular matrix drug discovery platform. The company has drug discovery partnerships with Dompe Farmaceutici and Takeda for advanced fibrotic liver diseases and fibrostenotic inflammatory bowel disease. Engitix was established in 2016 to commercialize research from the Institute for Liver and Digestive Health at University College London. The company is headquartered in WestWorks, London, UK. Giuseppe Mazza and Massimo Pinzani founded the company, and Giuseppe Mazza has been the CEO since 2016. | 6 anni |
Stephen Brindle | M | - |
Engitix Ltd.
Engitix Ltd. Miscellaneous Commercial ServicesCommercial Services Engitix Ltd. is a preclinical stage biopharma British company that is developing breakthrough therapies for fibrosis and solid tumors using its patient-centric human extracellular matrix drug discovery platform. The company has drug discovery partnerships with Dompe Farmaceutici and Takeda for advanced fibrotic liver diseases and fibrostenotic inflammatory bowel disease. Engitix was established in 2016 to commercialize research from the Institute for Liver and Digestive Health at University College London. The company is headquartered in WestWorks, London, UK. Giuseppe Mazza and Massimo Pinzani founded the company, and Giuseppe Mazza has been the CEO since 2016. | 8 anni |
Sonia Quaratino | M | - |
Engitix Ltd.
Engitix Ltd. Miscellaneous Commercial ServicesCommercial Services Engitix Ltd. is a preclinical stage biopharma British company that is developing breakthrough therapies for fibrosis and solid tumors using its patient-centric human extracellular matrix drug discovery platform. The company has drug discovery partnerships with Dompe Farmaceutici and Takeda for advanced fibrotic liver diseases and fibrostenotic inflammatory bowel disease. Engitix was established in 2016 to commercialize research from the Institute for Liver and Digestive Health at University College London. The company is headquartered in WestWorks, London, UK. Giuseppe Mazza and Massimo Pinzani founded the company, and Giuseppe Mazza has been the CEO since 2016. | 1 anni |
Massimo Pinzani | M | - |
Engitix Ltd.
Engitix Ltd. Miscellaneous Commercial ServicesCommercial Services Engitix Ltd. is a preclinical stage biopharma British company that is developing breakthrough therapies for fibrosis and solid tumors using its patient-centric human extracellular matrix drug discovery platform. The company has drug discovery partnerships with Dompe Farmaceutici and Takeda for advanced fibrotic liver diseases and fibrostenotic inflammatory bowel disease. Engitix was established in 2016 to commercialize research from the Institute for Liver and Digestive Health at University College London. The company is headquartered in WestWorks, London, UK. Giuseppe Mazza and Massimo Pinzani founded the company, and Giuseppe Mazza has been the CEO since 2016. | 8 anni |
Eduardo Bravo | M | - |
Engitix Ltd.
Engitix Ltd. Miscellaneous Commercial ServicesCommercial Services Engitix Ltd. is a preclinical stage biopharma British company that is developing breakthrough therapies for fibrosis and solid tumors using its patient-centric human extracellular matrix drug discovery platform. The company has drug discovery partnerships with Dompe Farmaceutici and Takeda for advanced fibrotic liver diseases and fibrostenotic inflammatory bowel disease. Engitix was established in 2016 to commercialize research from the Institute for Liver and Digestive Health at University College London. The company is headquartered in WestWorks, London, UK. Giuseppe Mazza and Massimo Pinzani founded the company, and Giuseppe Mazza has been the CEO since 2016. | 4 anni |
Gianluca Rossetti | M | - |
Engitix Ltd.
Engitix Ltd. Miscellaneous Commercial ServicesCommercial Services Engitix Ltd. is a preclinical stage biopharma British company that is developing breakthrough therapies for fibrosis and solid tumors using its patient-centric human extracellular matrix drug discovery platform. The company has drug discovery partnerships with Dompe Farmaceutici and Takeda for advanced fibrotic liver diseases and fibrostenotic inflammatory bowel disease. Engitix was established in 2016 to commercialize research from the Institute for Liver and Digestive Health at University College London. The company is headquartered in WestWorks, London, UK. Giuseppe Mazza and Massimo Pinzani founded the company, and Giuseppe Mazza has been the CEO since 2016. | 2 anni |
Grafico relazionale
Relazione in diverse aziende
Relazioni precedenti
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
Juan Pedro Rodriguez Serrate | M | - |
BlueCrest Capital Management Ltd. (Jersey)
BlueCrest Capital Management Ltd. (Jersey) Investment ManagersFinance BlueCrest Capital Management Ltd. (BlueCrest) is a single-family office headquartered in St. Helier, UK. They are a subsidiary of WHR Investments Ltd., ultimately owned by BC Cayman Charitable Trust in Cayman Islands. The firm was previously a hedge fund management firm and in 2015, Michael Platt decided to turn BlueCrest into a firm that only managed his own money and money that belongs to BlueCrest partners and employees. | 2 anni |
Tom Reusch | M | - |
BlueCrest Capital Management Ltd. (Jersey)
BlueCrest Capital Management Ltd. (Jersey) Investment ManagersFinance BlueCrest Capital Management Ltd. (BlueCrest) is a single-family office headquartered in St. Helier, UK. They are a subsidiary of WHR Investments Ltd., ultimately owned by BC Cayman Charitable Trust in Cayman Islands. The firm was previously a hedge fund management firm and in 2015, Michael Platt decided to turn BlueCrest into a firm that only managed his own money and money that belongs to BlueCrest partners and employees. | 2 anni |
Statistiche
Paese | Relazioni | % del totale |
---|---|---|
Regno Unito | 9 | 100.00% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Mike E. Platt
- Contatti personali